


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claim 1**                      (Previously Presented)                      A compound of formula I



in which

R<sup>1</sup> is H, OH, CN, Hal, CONHR, OB, CO<sub>2</sub>B, CF<sub>3</sub>, NR<sub>2</sub>, NRCOR, NRCOOR or NRCONR<sub>2</sub>,

R<sup>2</sup> is NR<sub>2</sub>, NRCOR, NRCOOR, NRCONR<sub>2</sub>, NO<sub>2</sub>, NRSO<sub>2</sub>R<sub>2</sub>, NRCSR or NRCSNR<sub>2</sub>,

R<sup>3</sup> is H, OH, CN, Hal, CONHR, OB, CO<sub>2</sub>B, CF<sub>3</sub>, NO<sub>2</sub>, NR<sub>2</sub>, NRCOR, NRCOOR or NRCONR<sub>2</sub>,

R, independently of one another, are H, B, Het or Ar,

A is a straight-chain or branched, mono- or polyunsaturated carbon chain having 2, 3, 4, 5, or 6 carbon atoms,

B is a straight-chain or branched alkyl radical having 1, 2, 3, 4, 5 or 6 carbon atoms,

a pharmaceutically usable prodrug, salt thereof, or a mixture thereof in all ratios.

**Claim 2 (Previously Presented)** A compound of formula I according to Claim 1, wherein  $R^1$  is CN or Hal.

**Claim 3 (Previously Presented)** A compound of formula I according to Claim 1, wherein  $R^3$  is H.

**Claim 4 (Previously Presented)** A compound of formula I according to Claim 1 wherein  $R^2$  is NRCOR or NR<sub>2</sub>COOR.

**Claim 5 (Previously Presented)** A compound of formula I according to Claim 1, wherein A is  $(CH_2)_m$ , where  $m = 2, 3, 4, 5$  or  $6$ .

**Claim 6 (Previously Presented)** A compound of formula I according to Claim 1, wherein  $R^1$  is CN or Hal, and  $R^3$  is H.

**Claim 7 (Previously Presented)** A compound of formula I according to Claim 1, wherein  $R^1$  is CN,  $R^3$  is H, and A is  $(CH_2)_m$ , where  $m = 4$ .

**Claim 8 (Previously Presented)** A compound of formula I according to Claim 1, wherein  $R^1$  is in position 5 of the indole radical.

**Claim 9 (Previously Presented)** A compound which is  
N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)methylamide,

§Appl. No. 10/551,997  
Amdt. dated November 30, 2010  
Reply to Office Action of, August 30, 2010

ethyl (6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,


methyl N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)carbamate,

N-(6-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-2-oxo-2H-chromen-3-yl)-2,2-dimethylpropionamide,

3-{4-[4-(3-amino-2-oxo-2H-chromen-6-yl)piperazin-1-yl]butyl}-1H-indole-5-carbonitrile,

or a pharmaceutically usable prodrug, or salt thereof.

**Claim 10 (Previously Presented)** A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting a compound of formula II




in which R<sup>2</sup> and R<sup>3</sup> are as defined in Claim 1, with a compound of formula III

§Appl. No. 10/551,997


Amdt. dated November 30, 2010

Reply to Office Action of, August 30, 2010




in which R<sup>1</sup> and A are as defined in Claim 1, and L is Cl, Br, I, OH or a reactively esterified OH group or another readily nucleophilically substitutable leaving group.

**Claim 11 (Previously Presented)** A process for the preparation of compounds of the formula I according to Claim 1, comprising reacting a compound of formula IV




in which R<sup>3</sup> is as defined in Claim 1, and R<sup>4</sup> is an amino-protecting group or H, in a Michael-analogous reaction, with ethyl nitroacetate and diethylammonium chloride, and subsequently reducing the nitro group to give a compound of formula V



and reacting the compound of formula V with a compound conforming to formula III

§Appl. No. 10/551,997  
Amdt. dated November 30, 2010  
Reply to Office Action of, August 30, 2010



in which R<sup>1</sup> and A are as defined in Claim 1, and L is Cl, Br, I, OH or a reactively esterified OH group or another readily nucleophilically substitutable leaving group.

**Claim 12** (Canceled)

**Claim 13** (Previously Presented) A pharmaceutical composition, comprising an effective amount of a compound of the formula I according to Claim 1, optionally in addition to one or more inert excipients, adjuvants and/or diluents, and a pharmaceutically acceptable carrier.

**Claim 14** (Canceled)

**Claim 15** (Previously Presented) A process for the preparation of a composition according to Claim 13, comprising combining a compound of formula I with one or more inert excipients and/or diluents by non-chemical methods.

**Claim 16** (Canceled)

**Claim 17** (Currently Amended) A method for treating depression, strokes, cerebral ischaemia, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease,

§Appl. No. 10/551,997  
Amdt. dated November 30, 2010  
Reply to Office Action of, August 30, 2010

~~Alzheimer's disease, amyotrophic lateral sclerosis, obsessive compulsive disorder, or tardive dyskinesia, comprising administering to a host in need thereof a compound according to Claim 1.~~

**Claim 18 (Canceled)**

**Claim 19. (Currently Amended)** A method for treating ~~depression, strokes, extrapyramidal motor side effects of neuroleptics and of Parkinson's disease, or Alzheimer's disease~~ schizophrenia, comprising administering to a host in need thereof a compound according to Claim 1.

**Claim 20. (Previously Presented)** A compound according to Claim 1 or a pharmaceutically acceptable salt thereof.

**Claim 21. (Previously Presented)** A compound according to Claim 9 or a pharmaceutically acceptable salt thereof.